TOP > 外国特許検索 > BIOMARKER FOR DIAGNOSING MUSCLE DISEASE

BIOMARKER FOR DIAGNOSING MUSCLE DISEASE NEW

外国特許コード F200010080
整理番号 5876
掲載日 2020年5月15日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP043998
国際公開番号 WO 2019111797
国際出願日 平成30年11月29日(2018.11.29)
国際公開日 令和元年6月13日(2019.6.13)
優先権データ
  • 特願2017-233758 (2017.12.5) JP
発明の名称 (英語) BIOMARKER FOR DIAGNOSING MUSCLE DISEASE NEW
発明の概要(英語) The present invention aims to provide a biomarker for early diagnosis of muscle disease. In addition, the present invention aims to provide a measurement technology that facilitates early diagnosis of muscle disease using said biomarker. The biomarker for muscle disease and comprising anti-DDB1 antibodies is useful as a biomarker for early diagnosis of muscle disease. A muscle disease detection method including a step in which anti-DDB1 antibodies in a blood sample derived from a test subject are detected is useful for the early detection of muscle disease. Ideally said muscle disease is polymyositis.
従来技術、競合技術の概要(英語) BACKGROUND ART
Inflammatory disease muscle (Inflammatory Myopathy; IM) is, as well as muscle, skin, as well as, lung, heart, including organs such as joints and systemic autoimmune disease. IM is, the Bohan and Peter 1975 years has been proposed (Non-Patent Document 1) the diagnostic criteria based on the classified polymyositis and dermatomyositis is included.
Generally myositis diagnosis, symptoms and clinical findings including muscle, and the inspection findings (specifically, the blood test (creatine kinase value, aldolase value of the myogenic enzyme values), physiological examination (needle and electromyogram), the image inspection (MRI), histological examination (muscle biopsy) ) is performed by. In a definitive diagnosis of the particular IM, muscle biopsy is an important role.
Recently, many myositis-specific antibody (myositis-specific autoantibodies; MSA) and myositis-associated autoantibodies (myositis-associated autoantibodies; MAA) has been reported. These MSA and the MAA, closely related to the clinical features are notable. So far, and the MSA in the sera of patients when MAA is detected, diagnostic of a disease, predicting the clinical course, in the early stages of disease and treatment determination is facilitated. Such autoantibodies, muscle weakness or abnormal laboratory finding easier identification of the cause of the symptoms and the like, or a muscle biopsy or the like of the early MRI aggressive the inspection criteria for determining the useful points.
On the other hand, damage to the DNA binding protein 1(DNA damage-binding protein 1; DDB1) DNA repair protein involved in the processes is found as. DDB1 Is, the relevance of the ultraviolet light (non-patent document 3 and 4), and the relevance of the virus infection is also reported (Non-Patent Document 5-11) respectively.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • HOSONO, Yuji
  • MIMORI, Tsuneyo
  • SASAI, Ran
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記までご連絡ください。

PAGE TOP

close
close
close
close
close
close